Riten Kumar/LinkedIn
Jan 10, 2026, 14:40
Last day at ASH25 from Riten Kumar
Riten Kumar, Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
”Last day at ASH25 – interesting subgroup analysis from the RENOVE trial, increased CRNM bleeding with apixaban and aspirin, but not NSAIDs and Sriveda Boyala Kuntla’s excellent presentation on infection associated thrombosis, finished off with trainees – past, present and future!”
All from ASH25 featured in Hemostasis Today.
-
Jan 10, 2026, 15:47Haematologica Journal Presents Review series on von Willebrand Disease
-
Jan 10, 2026, 15:15Stefan Gerner on Stroke Care and Subarachnoid Hemorrhage
-
Jan 10, 2026, 15:02Dr Manikanta Receives AHA Fellowship to Investigate Platelet-Dependent Nucleic Acid-Sensing Pathways
-
Jan 10, 2026, 08:56Shivanand Kumatagi Reflects on His Visit to Rela Hospital
-
Jan 10, 2026, 08:48Mitchell Elkind: Why Is The American Heart Association Holding a Brain Health Symposium?
-
Jan 10, 2026, 08:41Fiona Robinson Invites You to NBDF Webinar on Research Grants
-
Jan 10, 2026, 08:30Melissa Korn Takes Front Page Award for Her WSJ Piece on Experiencing a Pulmonary Embolism
-
Jan 10, 2026, 08:20Aymar Akilimali on Malaria in the Democratic Republic of Congo
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council